- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01497184
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
Study Overview
Detailed Description
Gene Transfer:
Gene transfer involves drawing blood from a transplant donor, and then separating out the T-cells using a machine. Researchers then perform a gene transfer to change the T-cells' DNA, and then inject the changed T-cells into the body of the patient receiving the transplant. This process is called a modified donor lymphocyte infusion (DLI).
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to 1 of 4 study arms, based on your age, treatment schedule, and disease status:
- Participants in Arm 1 will receive the T-cells by vein about 6-12 weeks after the stem cell transplant. (Adults participants only)
- Participants in Arm 2 will receive the T-cells by vein if, at any point, the disease comes back after stem cell transplant. Your doctor may decide that you need to receive chemotherapy before you are given the T-cells, in order to clear out the T-cells that are in your body already. This may help the infused T-cells work better. If more chemotherapy is needed, you will sign another informed consent document, which will the chemotherapy and its risks in detail. (Pediatric and adult participants eligible)
- Participants in Arm 3 will receive the T-cells by vein about 6-12 weeks after the stem cell transplant. (Pediatric participants [ages 1-17] only)
- Participants in Arm 4 will be given the T-cells as a scheduled infusion or if the disease comes back. This group is also scheduled to receive a stem cell transplant from a mismatched family member donor. (Pediatric and adult participants eligible)
Once you have been assigned to a study arm, you will be assigned to 1 of 4 dose levels of genetically-changed T-cells, based on when you joined this study. The first group of participants will receive the lowest dose of T-cells, and each new group will receive a higher dose of changed T-cells than the group before it, as long as no intolerable side effects were seen.
Chemotherapy and HSCT:
After your donor's stem cells have been successfully collected, you will be admitted to the hospital to receive chemotherapy and the HSCT. These procedures are not considered part of this research study. You will discuss these procedures with a study doctor and sign an informed consent document with specific details of the HSCT procedure and possible risks, at another time.
The T-cell Infusion:
After the HSCT, the study chair will decide when you will be eligible for the T-cell infusion. You must be at least 42 days past your transplant without any serious evidence of active graft versus host disease (GVHD). GVHD occurs when donor cells attack the cells of the person receiving the transplant.
Before the infusion, you will receive drugs to lower your risk of allergic reaction to the T-cells. Tylenol® (acetaminophen) will be given by mouth, and Benadryl® (diphenhydramine) may be given by mouth or by vein over a few minutes.
The T-cell infusion is given by vein, usually over 15-30 minutes. During the infusion, your vital signs will be checked. The infusion may be given on one day, or it may be divided into two parts at least 24 hours apart. The first part of the infusion will be a much smaller part to ensure that you have no immediate side effects.
Before the T cell infusion, you will receive drugs to lower your risk of allergic reaction to the T cells. Acetaminophen (Tylenol®) will be given by mouth, and diphenhydramine (Benadryl®) will be given by vein over a few minutes.
If your cancer returns after the transplant, you may receive an additional T-cell infusion. If you receive an additional T-cell infusion, the screening tests will be repeated. The study doctor will discuss the results of the repeated screening tests with you. If the screening tests show that you are not eligible to receive the additional T-cell infusion, other treatment options will be discussed with you.
Study Tests:
Within 3 days after the T-cell infusion, and then about 1 week, 2 weeks, 4 weeks, 8 weeks, 3 months, 6 months and 12 months after the T-cell infusion, the following tests will be performed:
- You will have a physical exam, including measurement of your height, weight, and vital signs.
- Your medical history will be recorded.
- Blood (about 4 tablespoons each time) will be drawn for research tests to check the level of the infused T-cells and to measure the number of B-cells and other (non-transplanted) T-cells.
- Blood (about 4 tablespoons each time) will be drawn for routine tests and tests of your blood chemistry, and blood sugars. During the 4 week, 8 week, 3 month, 6 month, and 12 month visits, part of this blood sample will be used for tests of certain protein levels. During the Month 3 visit, part of this blood sample will be used to check for HAMA immune system reactions. If you leave the study before the Month 3 visit, blood (about 1 tablespoon) may be collected for HAMA immune system reaction testing, if possible.
- You will have be checked for possible reactions to your treatment, including GVHD and graft failure. Graft failure occurs when donor cells may not be able to grow and multiply in your body. If this happens, there will be a high risk of infections and/or bleeding. If the number of white blood cells does not get back to high enough levels within 3 weeks after the transplant, more blood stem cells from the stem cell donor may be given.
- You may need a skin biopsy or an endoscopy to check for GVHD and/or graft failure, as well. To collect a skin biopsy, the biopsy area is numbed with anesthetic, and a small amount of skin is collected using a needle or scalpel. An endoscopy is an exam where you will be mildly sedated to allow a thin, flexible, lighted tube, called an endoscope, to be inserted inside the esophagus, stomach, and first part of the small intestine. This will allow the doctor to look for abnormal areas that might not be so easily seen in x-rays.
Within 3 months after the T-cell infusion, you will have CT scans and/or a bone marrow biopsy to check the status of the disease. An extra sample of bone marrow aspirate (about 2 teaspoons each time) will be drawn for research tests whenever a bone marrow aspirate/biopsy is being done if possible. These samples will be used for research tests to study how your immune system responds to the infusion of T-cells. To collect a bone marrow aspirate, an area of the hip is numbed with anesthetic, and a small amount of bone marrow is withdrawn through a large needle.
Length of Study:
You may continue taking part in this study for up to 3 months. You will be taken off study if the disease gets worse, you have any infections, or intolerable side effects occur.
Your participation on this study will be over once you have completed the planned study visits at 3 months after the T-cell infusion.
Retreatment:
If you are taken off study because the disease got worse, you may be able to enroll on study again once the highest tolerated dose of T-cells is found. If this happens, you will follow the same schedule for dosing and study tests as described above.
Long-Term Follow-Up:
For safety reasons, the U.S. Food and Drug Administration (FDA) requires that patients who receive infusions of stem cells treated with a gene transfer procedure must have long-term follow-up for at least 15 years after receiving the gene transfer.
This is an investigational study. The gene transfer or DLI (infusion with genetically-changed T-cells) are not commercially available or FDA approved for use in this type of disease. Their use in this study is considered investigational. The donor's leukapheresis procedure to collect cells for the manufacture of changed T-cells will be provided at no cost to you while you are on study.
Up to 140 patients (and up to 140 donors) will take part in this study. All will be enrolled at MD Anderson.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a history of CD19+ lymphoid malignancies that are primary refractory to treatment (do not achieve complete remission after first course of therapy) or are beyond first remission including second or greater remission or active disease. Patients in first remission are eligible if they are considered high risk, defined as any of the following detected at any time:1) Acute Lymphoblastic Leukemia (ALL) with translocations 9;22 or 4;11, hypodiploidy, complex karyotype, secondary leukemia developing after cytotoxic drug exposure,and/or evidence of minimal residual disease, 2) acute biphenotypic leukemia, or 3) double hit nonHodgkin's lymphoma. Non-Hodgkin's Lymphoma (NHL) in second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant). Double hit lymphomas in first remission or more advanced disease. Small Lymphocytic Lymphoma (SLL), or Chronic Lymphocytic Leukemia (CLL) with progressive disease following standard therapy.
- Age 1 to 65 years old.
- Lansky performance score >/= 60% for patients </= 16 years of age, or Zubrod performance 0-1 or Karnofsky greater than or equal to 80% for patients > 16 years of age.
- Patient or patient's legal representative, parent(s) or guardian able to provide written informed consent.
- Patient or patient's legal representative, parent(s) or guardian able to provide written informed consent for the long-term follow-up gene therapy study.
- Patient is planning to receive or has received an HLA-identical matched family, related haploidentical donor (</= 7/8 allele match), or at least 8/8 matched unrelated allogeneic HSCT.
Exclusion Criteria:
- Patients with known allergy to bovine or murine products.
- Active grade 2-4 acute GVHD at time of DLI.
- Systemic corticosteroid use within 72 hours of DLI unless required for physiologic replacement.
- Less than 80% donor chimerism from peripheral blood within 30 days of DLI administration, if T cells are made from allogeneic donor.
- Experiencing any new Grade >2 (CTC version 4) adverse neurologic, pulmonary, cardiac, gastrointestinal, renal or hepatic (excluding albumin) event within 24 hours prior to DLI.
- Currently using an investigational agent at time of DLI.
- Active infection defined as positive culture, if available, for bacteria, fungus, or virus within a 3-day period prior to DLI and/or fever greater than 38°C within 24 hours prior to DLI.
- Positive beta HCG in female of child-bearing potential defined as not post menopausal for 12 months or absence of previous surgical sterilization.
- Active CNS disease in patient with history of CNS malignancy.
- Positive serology for HIV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DLI (Adults)
Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
|
Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
Other Names:
Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
Other Names:
|
Experimental: DLI any time
Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
|
Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
Other Names:
Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
Other Names:
|
Experimental: DLI Pediatrics
Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
|
Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
Other Names:
Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
Other Names:
|
Experimental: DLI - Haplo-Identical Family Donor
Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
|
Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
Other Names:
Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated dose (MTD) of Donor Lymphocyte Infusion (DLI)
Time Frame: 3 months
|
MTD is highest dose level where 2 of 6 treated participants have dose limiting toxicity (DLT).
DLT defined as new adverse event attributable to donor lymphocyte infusion (DLI) grade 3 or > involving cardiopulmonary, gastrointestinal, hepatic (excluding albumin), neurological, or renal common toxicity criteria (CTC) version 4 parameters, lasts > 3 days and possibly related to DLI within 30 days of infusion.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Partow Kebriaei, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Lymphoma
- NHL
- ALL
- Leukemia
- Non-Hodgkin's Lymphoma
- Hematopoietic Stem Cell Transplantation
- HSCT
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Bone marrow transplant
- DLI
- Acute lymphoblastic leukemia
- CD19-specific T cells
- Small lymphocytic lymphoma
- Allogeneic donor lymphocyte infusion
- T cell infusion
- B-Lineage lymphoid malignancies
- CD19+ lymphoid malignancies
- Biphenotypic leukemia CD19+ in advanced remission
- Mantle cell lymphoma with active disease at time of transplant
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-0525
- NCI-2012-00015 (Registry Identifier: NCI CTRP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
Clinical Trials on HSCT
-
Federal Research Institute of Pediatric Hematology...Physicians, Innovations, Science for Children FundRecruitingAcute Myeloid Leukemia, ChildhoodRussian Federation
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
bluebird bioTerminatedCerebral Adrenoleukodystrophy (CALD) | Adrenoleukodystrophy (ALD) | X-Linked Adrenoleukodystrophy (X-ALD)United States, United Kingdom, Argentina, Canada, Germany, Italy, Netherlands
-
European Society for Blood and Marrow TransplantationRecruitingAutoimmune DiseasesFrance
-
Abramson Cancer Center at Penn MedicineMedtronicActive, not recruitingAtrial Fibrillation | Atrial Flutter | Hematopoietic Stem Cell TransplantUnited States
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
European Society for Blood and Marrow TransplantationCompletedAutoimmune DiseasesFrance
-
Wu XiaoxiongUnknown
-
Nanfang Hospital, Southern Medical UniversityZhujiang HospitalCompletedAcute Myeloid Leukemia | Risk Stratification
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma (DLBCL)United States